Skip to main content
. 2018 Dec;10(12):6677–6694. doi: 10.21037/jtd.2018.11.87

Figure 2.

Figure 2

Network diagrams for hazard ratio analyses of overall survival (A) and progression-free survival (B). Carbo, carboplatin; cis, cisplatin; doc, docetaxel; erlot, erlotinib; gem, gemcitabine; nab-tax, nab-paclitaxel; neci, necitumumab; tax, paclitaxel; vin, vinorelbine.